Wildcat Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Wildcat Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-295,613	Closed	-$257K	–	40
2019 Q2	$257K	Hold	295,613	–	–	0.11%	26
2019 Q1	$686K	Hold	295,613	–	–	0.4%	18
2018 Q4	$686K	Hold	295,613	–	–	0.45%	15
2018 Q3	$4.38M	Hold	295,613	–	–	3.38%	7
2018 Q2	$4.49M	Hold	295,613	–	–	3.43%	7
2018 Q1	$5.55M	Buy	+295,613	New	+$5.17M	4.58%	6

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Wildcat Capital Management's SNNA Position: Q3 2019 in Review

Wildcat Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 295,613 shares — an estimated $257K sold.

Wildcat Capital Management first reported a position in SNNA in Q1 2018 and held it in 6 quarters. The position peaked at $5.55M in Q1 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Wildcat Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Wildcat Capital Management sold 295,613 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $257K.
Wildcat Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 6 quarters.
Wildcat Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $5.55M in Q1 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Wildcat Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.